These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 31591478)

  • 21. CHK1-targeted therapy to deplete DNA replication-stressed, p53-deficient, hyperdiploid colorectal cancer stem cells.
    Manic G; Signore M; Sistigu A; Russo G; Corradi F; Siteni S; Musella M; Vitale S; De Angelis ML; Pallocca M; Amoreo CA; Sperati F; Di Franco S; Barresi S; Policicchio E; De Luca G; De Nicola F; Mottolese M; Zeuner A; Fanciulli M; Stassi G; Maugeri-Saccà M; Baiocchi M; Tartaglia M; Vitale I; De Maria R
    Gut; 2018 May; 67(5):903-917. PubMed ID: 28389531
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identification and functional analysis of variants of a cancer/testis antigen LEMD1 in colorectal cancer stem-like cells.
    Takeda R; Hirohashi Y; Shen M; Wang L; Ogawa T; Murai A; Yamamoto E; Kubo T; Nakatsugawa M; Kanaseki T; Tsukahara T; Nishidate T; Okita K; Kutomi G; Sato N; Takemasa I; Torigoe T
    Biochem Biophys Res Commun; 2017 Apr; 485(3):651-657. PubMed ID: 28219643
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Co-expression of Lgr5 and CXCR4 characterizes cancer stem-like cells of colorectal cancer.
    Wu W; Cao J; Ji Z; Wang J; Jiang T; Ding H
    Oncotarget; 2016 Dec; 7(49):81144-81155. PubMed ID: 27835894
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mithramycin A Inhibits Colorectal Cancer Growth by Targeting Cancer Stem Cells.
    Quarni W; Dutta R; Green R; Katiri S; Patel B; Mohapatra SS; Mohapatra S
    Sci Rep; 2019 Oct; 9(1):15202. PubMed ID: 31645574
    [TBL] [Abstract][Full Text] [Related]  

  • 25. UCN-01 enhances cytotoxicity of irinotecan in colorectal cancer stem-like cells by impairing DNA damage response.
    Signore M; Buccarelli M; Pilozzi E; De Luca G; Cappellari M; Fanciulli M; Goeman F; Melucci E; Biffoni M; Ricci-Vitiani L
    Oncotarget; 2016 Jul; 7(28):44113-44128. PubMed ID: 27286453
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Coexistent mutations of KRAS and PIK3CA affect the efficacy of NVP-BEZ235, a dual PI3K/MTOR inhibitor, in regulating the PI3K/MTOR pathway in colorectal cancer.
    Kim A; Lee JE; Lee SS; Kim C; Lee SJ; Jang WS; Park S
    Int J Cancer; 2013 Aug; 133(4):984-96. PubMed ID: 23475782
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Metformin targets gastric cancer stem cells.
    Courtois S; Durán RV; Giraud J; Sifré E; Izotte J; Mégraud F; Lehours P; Varon C; Bessède E
    Eur J Cancer; 2017 Oct; 84():193-201. PubMed ID: 28822889
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting the Wnt Pathway and Cancer Stem Cells with Anti-progastrin Humanized Antibodies as a Potential Treatment for K-RAS-Mutated Colorectal Cancer.
    Prieur A; Cappellini M; Habif G; Lefranc MP; Mazard T; Morency E; Pascussi JM; Flacelière M; Cahuzac N; Vire B; Dubuc B; Durochat A; Liaud P; Ollier J; Pfeiffer C; Poupeau S; Saywell V; Planque C; Assenat E; Bibeau F; Bourgaux JF; Pujol P; Sézeur A; Ychou M; Joubert D
    Clin Cancer Res; 2017 Sep; 23(17):5267-5280. PubMed ID: 28600477
    [No Abstract]   [Full Text] [Related]  

  • 29. Tankyrase Inhibition Blocks Wnt/β-Catenin Pathway and Reverts Resistance to PI3K and AKT Inhibitors in the Treatment of Colorectal Cancer.
    Arqués O; Chicote I; Puig I; Tenbaum SP; Argilés G; Dienstmann R; Fernández N; Caratù G; Matito J; Silberschmidt D; Rodon J; Landolfi S; Prat A; Espín E; Charco R; Nuciforo P; Vivancos A; Shao W; Tabernero J; Palmer HG
    Clin Cancer Res; 2016 Feb; 22(3):644-56. PubMed ID: 26224873
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cancer stem cells in colorectal cancer from pathogenesis to therapy: controversies and perspectives.
    Fanali C; Lucchetti D; Farina M; Corbi M; Cufino V; Cittadini A; Sgambato A
    World J Gastroenterol; 2014 Jan; 20(4):923-42. PubMed ID: 24574766
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cancer stem cell-related gene expression as a potential biomarker of response for first-in-class imipridone ONC201 in solid tumors.
    Prabhu VV; Lulla AR; Madhukar NS; Ralff MD; Zhao D; Kline CLB; Van den Heuvel APJ; Lev A; Garnett MJ; McDermott U; Benes CH; Batchelor TT; Chi AS; Elemento O; Allen JE; El-Deiry WS
    PLoS One; 2017; 12(8):e0180541. PubMed ID: 28767654
    [TBL] [Abstract][Full Text] [Related]  

  • 32. IFN-α potentiates the direct and immune-mediated antitumor effects of epigenetic drugs on both metastatic and stem cells of colorectal cancer.
    Buoncervello M; Romagnoli G; Buccarelli M; Fragale A; Toschi E; Parlato S; Lucchetti D; Macchia D; Spada M; Canini I; Sanchez M; Falchi M; Musella M; Biffoni M; Belardelli F; Capone I; Sgambato A; Vitiani LR; Gabriele L
    Oncotarget; 2016 May; 7(18):26361-73. PubMed ID: 27028869
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.
    García-García C; Rivas MA; Ibrahim YH; Calvo MT; Gris-Oliver A; Rodríguez O; Grueso J; Antón P; Guzmán M; Aura C; Nuciforo P; Jessen K; Argilés G; Dienstmann R; Bertotti A; Trusolino L; Matito J; Vivancos A; Chicote I; Palmer HG; Tabernero J; Scaltriti M; Baselga J; Serra V
    Clin Cancer Res; 2015 Dec; 21(24):5499-5510. PubMed ID: 26272063
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecular subtypes of colorectal cancer in pre-clinical models show differential response to targeted therapies: Treatment implications beyond KRAS mutations.
    Pal R; Wei N; Song N; Wu S; Kim RS; Wang Y; Gavin PG; Lucas PC; Srinivasan A; Allegra CJ; Jacobs SA; Paik S; Schmitz JC; Pogue-Geile KL
    PLoS One; 2018; 13(8):e0200836. PubMed ID: 30118499
    [TBL] [Abstract][Full Text] [Related]  

  • 35. MiR-148a suppressed cell invasion and migration via targeting WNT10b and modulating β-catenin signaling in cisplatin-resistant colorectal cancer cells.
    Shi L; Xi J; Xu X; Peng B; Zhang B
    Biomed Pharmacother; 2019 Jan; 109():902-909. PubMed ID: 30551544
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tyr1068-phosphorylated epidermal growth factor receptor (EGFR) predicts cancer stem cell targeting by erlotinib in preclinical models of wild-type EGFR lung cancer.
    Sette G; Salvati V; Mottolese M; Visca P; Gallo E; Fecchi K; Pilozzi E; Duranti E; Policicchio E; Tartaglia M; Milella M; De Maria R; Eramo A
    Cell Death Dis; 2015 Aug; 6(8):e1850. PubMed ID: 26247735
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Activation of WNT/β-catenin signaling results in resistance to a dual PI3K/mTOR inhibitor in colorectal cancer cells harboring PIK3CA mutations.
    Park YL; Kim HP; Cho YW; Min DW; Cheon SK; Lim YJ; Song SH; Kim SJ; Han SW; Park KJ; Kim TY
    Int J Cancer; 2019 Jan; 144(2):389-401. PubMed ID: 29978469
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dual Inhibition of Myc Transcription and PI3K Activity Effectively Targets Colorectal Cancer Stem Cells.
    Gaggianesi M; Mangiapane LR; Modica C; Pantina VD; Porcelli G; Di Franco S; Lo Iacono M; D'Accardo C; Verona F; Pillitteri I; Turdo A; Veschi V; Brancato OR; Muratore G; Pistone G; Bongiorno MR; Todaro M; De Maria R; Stassi G
    Cancers (Basel); 2022 Jan; 14(3):. PubMed ID: 35158939
    [TBL] [Abstract][Full Text] [Related]  

  • 39. B591, a novel specific pan-PI3K inhibitor, preferentially targets cancer stem cells.
    Zhou H; Yu C; Kong L; Xu X; Yan J; Li Y; An T; Gong L; Gong Y; Zhu H; Zhang H; Yang X; Li Y
    Oncogene; 2019 May; 38(18):3371-3386. PubMed ID: 30635656
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer.
    Yang H; Higgins B; Kolinsky K; Packman K; Bradley WD; Lee RJ; Schostack K; Simcox ME; Kopetz S; Heimbrook D; Lestini B; Bollag G; Su F
    Cancer Res; 2012 Feb; 72(3):779-89. PubMed ID: 22180495
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.